Larimar Therapeutics Reports Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 7c
August 14, 2025 7:24 AM EDTLarimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.41), $0.07 better than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.
... More